ArticleNPJ biofilms and microbiomes2021
Human organoid biofilm model for assessing antibiofilm activity of novel agents.
Article in NPJ biofilms and microbiomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Animal organoids as models for integrated One Health research.One health (Amsterdam, Netherlands) · 2026Review
- Simulating the host niche: balancing complexity and control in the experimental evolution of antibiotic resistance and pathoadaptation.Microbiology (Reading, England) · 2026Review
- Targeting the stringent response alters gene expression and extracellular vesicle RNA inMicrobiology spectrum · 2026Article
- Bacterial Biofilm and Titanium Implants: Mechanisms, Clinical Problems, and Surface Modification Strategies.Materials (Basel, Switzerland) · 2026Review
- Biofilm-Host Immune Crosstalk at the Diabetic Foot Ulcer Interface: Molecular Mechanisms, Immune Evasion, and Next-Generation Anti-Biofilm Strategies.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Use of the bacteriophage-derived endolysin CHAPK-SH3blys as a potent novel treatment for biofilm-associatedMicrobiology spectrum · 2025Article
- Synthetic host defense peptide inhibits SARS-CoV-2 replicationAntimicrobial agents and chemotherapy · 2025Article
- Synthetic peptides targeting a mast cell-specific G protein-coupled receptor MRGPRB2 display anti-infective potential.Cell biomaterials · 2025Article
- From gut to liver: organoids as platforms for next-generation toxicology assessment vehicles for xenobiotics.Stem cell research & therapy · 2025Review
- DJK-5, an anti-biofilm peptide, increases Staphylococcus aureus sensitivity to colistin killing in co-biofilms with Pseudomonas aeruginosa.NPJ biofilms and microbiomes · 2025Article
- Prediction of SafD adhesin strong binding peptides for pilus proteins assembly suppression in the prevention ofIn silico pharmacology · 2025Article
- Towards improved biofilm models.Nature reviews. Microbiology · 2025Review
- Constructing two bifunctional tooth-targeting antimicrobial peptides for caries management: an in vitro study.Clinical oral investigations · 2024Article
- Effect of baicalin on eradicating biofilms of bovine milk derived Acinetobacter lwoffii.BMC veterinary research · 2024Article
- Elimination of Pathogen Biofilms via Postbiotics from Lactic Acid Bacteria: A Promising Method in Food and Biomedicine.Microorganisms · 2024Review
- Elimination of detached Listeria monocytogenes from the biofilm on stainless steel surfaces during milk and cheese processing using natural plant extracts.Scientific reports · 2024Article
- A Platform for Testing the Biocompatibility of Implants: Silicone Induces a Proinflammatory Response in a 3D Skin Equivalent.Biomedicines · 2024Article
- Antibiotic failure: Beyond antimicrobial resistance.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023Review
- Alternatives to animal models to study bacterial infections.Folia microbiologica · 2023Review
- Antibacterial activities of anthraquinones: structure-activity relationships and action mechanisms.RSC medicinal chemistry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 3 countries.
Funding
Abstract
Bacterial biofilms cause 65% of all human infections and are highly resistant to antibiotic therapy but lack specific treatments. To provide a human organoid model for studying host-microbe interplay and enabling screening for novel antibiofilm agents, a human epidermis organoid model with robust methicillin-resistant Staphylococcus aureus (MRSA) USA300 and Pseudomonas aeruginosa PAO1 biofilm was developed. Treatment of 1-day and 3-day MRSA and PAO1 biofilms with antibiofilm peptide DJK-5 significantly and substantially reduced the bacterial burden. This model enabled the screening of synthetic host defense peptides, revealing their superior antibiofilm activity against MRSA compared to the antibiotic mupirocin. The model was extended to evaluate thermally wounded skin infected with MRSA biofilms resulting in increased bacterial load, cytotoxicity, and pro-inflammatory cytokine levels that were all reduced upon treatment with DJK-5. Combination treatment of DJK-5 with an anti-inflammatory peptide, 1002, further reduced cytotoxicity and skin inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.